Can Polyps Cause a Positive Cologuard Test?

Polyps are one of the main reasons Cologuard returns a positive result. The test is specifically designed to detect DNA shed by abnormal growths in the colon, including precancerous polyps called adenomas. But Cologuard’s relationship with polyps is complicated: it catches most colorectal cancers while missing more than half of the precancerous polyps it was built to find, and a substantial number of positive results lead to follow-up colonoscopies that turn up nothing clinically worrying at all.

How Polyps Trigger a Positive Result

Cologuard is a multitarget stool DNA test, meaning it looks for several biological signals at once. Cells lining the colon are constantly being shed into stool, and abnormal growths like adenomatous polyps, serrated polyps, and cancers shed cells carrying altered DNA. Cologuard’s laboratory assays target specific genetic and epigenetic changes in that shed DNA to distinguish neoplastic tissue from normal tissue.¹ The test also includes an immunochemical component that detects hidden blood in the stool, which polyps and cancers can produce through surface erosion or fragile blood vessels.

So a polyp does not have to be cancerous to trigger a positive Cologuard. Any polyp shedding enough abnormal DNA or causing enough microscopic bleeding can flip the test. The catch is that smaller, earlier-stage polyps tend to shed less material, which is why the test’s ability to find them varies dramatically depending on polyp size and type.

What Cologuard Actually Catches and What It Misses

Cologuard performs well for established colorectal cancer. In a large multicenter screening trial of nearly 10,000 adults, the test detected about 92% of colorectal cancers.² That is reassuring for the test’s primary purpose. But colorectal cancer screening is supposed to be about prevention as much as detection, and that means catching precancerous polyps before they turn malignant.

Here the numbers are less encouraging. That same trial found Cologuard detected fewer than half of all large advanced adenomas, with a sensitivity of roughly 42%.² A systematic review using health technology assessment methods reported similar figures: Cologuard showed 92.3% sensitivity for colorectal cancer but only 46.4% sensitivity for cancer or advanced precancerous lesions combined.³ In plain terms, if you have an advanced adenoma, Cologuard has roughly a coin-flip chance of flagging it.

For smaller, non-advanced polyps, the detection rate drops further. The test is positively associated with larger tumor size and greater number of polyps, meaning it performs better as the disease burden grows.⁴ A small, solitary polyp under one centimeter is much less likely to produce enough altered DNA or bleeding to push the test over its threshold.

Why So Many Positive Tests Find Nothing Significant

One of the most common experiences after a positive Cologuard is going in for a colonoscopy and being told everything looks fine. This happens frequently. One real-world study found that roughly 62% of patients who had a positive Cologuard had no significant findings on their follow-up colonoscopy, suggesting a considerable rate of false positives.⁵ A retrospective review of patients with positive results reported that 68% had either a completely normal colonoscopy or only hyperplastic polyps, which are generally considered harmless. About 90% had normal findings, hyperplastic polyps, or non-advanced adenomas.⁶

The test’s specificity for colorectal cancer runs around 84-87%, depending on the study and the comparison used.³ That means for every hundred people without cancer or advanced lesions who take the test, roughly 13 to 16 will get a positive result anyway. In a screening population where serious disease is uncommon, those false positives add up fast.

What actually causes these false positives? The test is picking up real biological signals, but they might come from sources other than dangerous polyps. Non-neoplastic conditions that cause colonic inflammation or bleeding, like hemorrhoids, inflammatory bowel disease, diverticulosis, and even upper gastrointestinal conditions, can all contribute altered DNA or blood to the stool. The test cannot tell where the blood or DNA came from; it just registers the markers.

When the Source Is Not Even in the Colon

One underappreciated wrinkle is that a positive Cologuard can be driven by problems in the upper digestive tract. A study of 100 consecutive patients with positive Cologuard results found that only 52% had positive findings on colonoscopy, while 70% had significant findings on upper gastrointestinal endoscopy. Twenty-eight percent had abnormalities on both upper and lower endoscopy, and just 6% had completely normal findings on both.⁷

This finding is striking because the standard follow-up for a positive Cologuard is a colonoscopy, which only examines the lower digestive tract. If the positive result was triggered by bleeding from a stomach ulcer, esophageal condition, or other upper GI problem, the colonoscopy could come back clean while the underlying issue goes unaddressed. This is still an area where clinical practice is catching up with the data, and most guidelines do not yet recommend routine upper endoscopy after a positive stool test. But if your colonoscopy turns up nothing, it is worth discussing with your doctor whether upper GI evaluation makes sense.

Polyps That Get Missed Despite a Negative Test

The flip side of false positives is false negatives: polyps that exist but do not trigger a positive result. Because Cologuard catches fewer than half of advanced adenomas, a clean test does not guarantee a clean colon. A study looking at patients who had a negative Cologuard but then underwent colonoscopy found that about 8.4% had advanced adenomas and roughly 1% had colorectal cancer. Advanced adenomas that were missed tended to be associated with a higher number of polyps and larger polyp size, and proximal lesions in the right side of the colon, particularly near the hepatic flexure and transverse colon, were more common among the missed cases.⁸

Why would a larger polyp go undetected? Location matters. Right-sided colon lesions may shed DNA that degrades more as it travels the full length of the colon before reaching the stool sample. Polyp biology also plays a role: some adenomas are flat or sessile rather than protruding, and they may produce different patterns of DNA shedding. Serrated polyps, a category increasingly recognized as a precursor to a distinct pathway of colon cancer, can be particularly tricky for stool-based tests to detect because they may not bleed as much and their molecular alterations can differ from the classic adenoma markers Cologuard targets.

Sample Handling and Its Quiet Effect on Results

Something most patients never think about is how sample quality affects accuracy. Cologuard requires you to collect a stool sample at home and mail it in a stabilizing buffer to a laboratory. Research on fecal DNA testing has shown that storing stool samples at room temperature for 36 hours or more significantly reduces the amount of recoverable human DNA, and some assay components are much more vulnerable to this degradation than others. In one study, an assay measuring DNA integrity lost 82% of its sensitivity when samples were stored at room temperature too long, while point mutation markers held up better.⁹

The practical takeaway: if you leave your sample sitting around before shipping it, or if it gets delayed in transit during hot weather, the DNA may degrade enough to affect the test’s ability to detect a polyp that is actually there. The kit includes a preservative buffer designed to prevent this, and the instructions emphasize shipping the sample promptly. It is one of those boring logistical details that can genuinely change whether your result is reliable.

What Happens After a Positive Cologuard

Regardless of what caused the positive result, every abnormal Cologuard needs a follow-up colonoscopy. The US Preventive Services Task Force makes this explicit: when stool-based tests reveal abnormal results, follow-up with colonoscopy is needed for further evaluation.¹⁰ You cannot just repeat the Cologuard and hope for a different result. The positive test has already told you something was found in the stool, and a colonoscopy is the only way to determine whether that something is a dangerous polyp, a cancer, a harmless finding, or nothing at all.

The reality of what colonoscopy finds after a positive Cologuard spans a wide range. In one retrospective study, only 1.3% of patients with a positive test were found to have colorectal cancer, and 6.4% had advanced adenomas. The positive predictive value for precancerous lesions plus cancer combined was 7.7%.⁶ That means roughly 1 in 13 people with a positive Cologuard will have something that needs treatment. For the majority, the colonoscopy brings reassurance, though it is an invasive procedure with its own costs, preparation, and small risks.

Getting that follow-up colonoscopy done in a timely manner matters. A positive stool-based test result requires timely follow-up colonoscopy to realize the full benefits of screening.¹¹ Delays can allow polyps or early cancers to progress, and research has documented that a meaningful fraction of patients with positive stool tests do not complete the recommended colonoscopy, sometimes due to anxiety about the procedure, access barriers, or a misunderstanding that the stool test was the final answer rather than a first step.

People With a Prior Normal Colonoscopy

An interesting subset of patients are those who had a normal colonoscopy in the past and then get a positive Cologuard during subsequent screening. You might expect these people to have very low rates of significant findings, but the picture is more nuanced. One study examining patients who had a positive Cologuard after a previously normal colonoscopy found that 30% had advanced adenomas on follow-up, though none had colorectal cancer.¹² Compared to patients without a prior colonoscopy, these individuals did have fewer adenomas overall and fewer advanced adenomas per person, which is consistent with the idea that an earlier colonoscopy removed some precursors. But the fact that nearly a third still had advanced adenomas reinforces that a positive Cologuard is worth taking seriously even if your last colonoscopy was clean.

Polyps can grow between screenings, and the colon is a dynamic environment. A prior normal colonoscopy reduces your risk but does not eliminate it, especially if several years have passed.

How Next-Generation Tests Are Changing the Picture

The original version of Cologuard was approved by the FDA in 2014. Since then, newer iterations and alternative stool-based tests have been developed with the goal of improving both sensitivity for precancerous polyps and specificity to reduce false positives. Recent clinical trials have evaluated an improved multitarget stool DNA test alongside a novel multitarget stool eRNA test and a blood-based test. The updated stool DNA test showed 93.5% sensitivity for colorectal cancer with 90.6% specificity, while the eRNA test reached 94.4% sensitivity with 87.9% specificity. For advanced polyps, however, both remained in the mid-40% range for sensitivity, at 43.4% and 45.9% respectively.¹³

The specificity improvements are meaningful. Bumping specificity from 84-87% up to around 90% means fewer people getting unnecessary colonoscopies after false positives, which translates to less anxiety, fewer costs, and better trust in the screening process overall. But the stubborn ceiling around 43-46% sensitivity for advanced polyps remains the central limitation of stool-based DNA testing. Nearly six in ten advanced precancerous polyps still slip through. For people at higher risk of colon cancer due to family history or personal history, this limitation tilts the balance toward colonoscopy as the preferred screening method.

Cologuard Versus Colonoscopy for Polyp Detection

Colonoscopy remains the gold standard for finding and removing polyps, because the gastroenterologist can visualize the entire colon, biopsy suspicious tissue, and remove polyps during the same procedure. No stool test, no matter how advanced, can remove a polyp. If Cologuard finds something, you still need a colonoscopy. If Cologuard misses something, the polyp stays and grows until the next screening or until symptoms develop.

The USPSTF recommendation acknowledges this trade-off. Modeling estimates show that screening with the stool DNA test annually would result in more colonoscopies overall than annual screening with FIT, because Cologuard’s lower specificity generates more positive results requiring follow-up. On the other hand, many people who are eligible for screening never get a colonoscopy at all. For someone who would otherwise skip screening entirely, Cologuard offers a lower-barrier entry point.¹⁰ A screening test that catches 92% of cancers and 42% of advanced adenomas in people who would have been screened by nothing is far better than an unperformed colonoscopy that catches 0% of anything.

When Anxiety About a Positive Result Is the Real Problem

The psychological dimension of false positives deserves mention. Excessive false positives may contribute negatively by increasing patient anxiety, leading to unnecessary procedures, and reducing willingness to participate in future screenings.⁵ If you get a positive Cologuard and the colonoscopy finds nothing, the relief is real, but so is the frustration of having gone through bowel prep, sedation, a day off work, and possibly a significant out-of-pocket bill for what turned out to be a false alarm. Some patients become skeptical of screening altogether after this experience, which is the opposite of what the healthcare system intended.

Understanding the base rates helps manage expectations. If you are an average-risk adult getting screened, the odds that a positive Cologuard represents colorectal cancer are quite low, probably in the range of 1-4%. The odds that it represents an advanced adenoma are modestly higher but still under 10% in most real-world studies. The most likely outcome, by a wide margin, is that the colonoscopy will be reassuring. Knowing that going in does not make the false alarm painless, but it can reduce the dread between the phone call about your results and the colonoscopy appointment.

Screening Intervals and Repeat Testing

The USPSTF recommends Cologuard every one to three years for average-risk adults, noting that this interval provides a reasonable balance of benefit per follow-up colonoscopy compared with no screening.¹⁰ The three-year interval is more commonly used in practice, partly because of cost considerations and partly because the test is designed to detect changes that develop slowly. A small polyp that forms and is missed on one round of testing might grow large enough to shed detectable DNA by the next round three years later, or it might not progress at all.

One thing to keep in mind: a negative Cologuard does not reset the clock in the same way a negative colonoscopy does. After a clean colonoscopy, most guidelines recommend waiting ten years before the next screening in average-risk adults. After a negative Cologuard, you are back for another test in one to three years, precisely because the test misses a meaningful fraction of precancerous polyps and needs repeated opportunities to catch what it might have missed the first time around.

1
Annual Review of Medicine. Fecal DNA Testing for Colorectal Cancer Screening
2
PubMed Central. Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: The importance of cancer prevention in addition to cancer detection – Section: Cologuard (multi-target stool DNA test for CRC)
3
PubMed Central. Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model for Rapid Relative Effectiveness Assessment – Section: Results
4
PubMed. Effectiveness of multitarget stool DNA versus faecal immunochemical testing alone in detecting colorectal cancer and advanced polyps: A systematic review – Section: RESULTS
5
PubMed Central. From Detection to Delay: Real-World Gaps in Post-Cologuard Colonoscopy Adherence – Section: Discussion
6
PubMed. Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer – Section: RESULTS
7
PubMed. The Role of UGI Endoscopy in the Workup of Patients With a Positive Cologuard Test in an Appalachian Population
8
PubMed. Factors Associated with Advanced Adenoma Detection by Colonoscopy After Negative Multitarget Stool DNA Testing – Section: RESULTS
9
Diagnostic Molecular Pathology. DNA Stabilization Is Critical for Maximizing Performance of Fecal DNA-Based Colorectal Cancer Tests – Section: Abstract
10
JAMA. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement – Section: Practice Considerations
11
Gastro Hep Advances. Adherence to Follow-Up Colonoscopy After a Positive Stool-Based Test in Patients Aged 45–49 Years – Section: Abstract
12
PubMed. The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy – Section: RESULTS
13
PubMed. Top advances of the year: Noninvasive colorectal cancer screening tests